These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26511990)

  • 21. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
    Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.
    Karron RA; Atwell JE; McFarland EJ; Cunningham CK; Muresan P; Perlowski C; Libous J; Spector SA; Yogev R; Aziz M; Woods S; Wanionek K; Collins PL; Buchholz UJ
    Am J Respir Crit Care Med; 2021 Mar; 203(5):594-603. PubMed ID: 32871092
    [No Abstract]   [Full Text] [Related]  

  • 23. Subunit and virus-like particle vaccine approaches for respiratory syncytial virus.
    Morrison TG; Walsh EE
    Curr Top Microbiol Immunol; 2013; 372():285-306. PubMed ID: 24362695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children.
    Karron RA; Luongo C; Mateo JS; Wanionek K; Collins PL; Buchholz UJ
    J Infect Dis; 2020 Jun; 222(1):82-91. PubMed ID: 31605113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and epidemiologic features of respiratory syncytial virus.
    Hall CB; Simőes EA; Anderson LJ
    Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Jung YJ; Jeeva S; Kwon YM; Seong BL; Kang SM
    Antiviral Res; 2019 Aug; 168():100-108. PubMed ID: 31150678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
    Harcourt JL; Karron RA; Tripp RA
    J Infect Dis; 2004 Dec; 190(11):1936-40. PubMed ID: 15529257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8
    Lee JY; Chang J
    J Microbiol; 2017 Nov; 55(11):900-908. PubMed ID: 29076066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
    Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR
    J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.
    Shan J; Britton PN; King CL; Booy R
    Influenza Other Respir Viruses; 2021 Jul; 15(4):539-551. PubMed ID: 33764693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
    Papi A; Ison MG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Campora L; Dezutter N; de Schrevel N; Fissette L; David MP; Van der Wielen M; Kostanyan L; Hulstrøm V;
    N Engl J Med; 2023 Feb; 388(7):595-608. PubMed ID: 36791160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
    Rossey I; Saelens X
    Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
    [No Abstract]   [Full Text] [Related]  

  • 38. Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice.
    Muralidharan A; Russell MS; Larocque L; Gravel C; Sauvé S; Chen Z; Li C; Chen W; Cyr T; Rosu-Myles M; Wang L; Li X
    Vaccine; 2019 Jul; 37(30):4031-4039. PubMed ID: 31186190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene-based vaccine approaches for respiratory syncytial virus.
    Loomis RJ; Johnson PR
    Curr Top Microbiol Immunol; 2013; 372():307-24. PubMed ID: 24362696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives.
    Vittucci AC; Zangari P; Ciarlitto C; Di Camillo C; Grandin A; Cotugno N; Marchili MR; Villani A
    Minerva Pediatr; 2018 Dec; 70(6):566-578. PubMed ID: 30334621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.